362 related articles for article (PubMed ID: 38559560)
1. The roles of lncRNAs and miRNAs in pancreatic cancer: a focus on cancer development and progression and their roles as potential biomarkers.
Jafari S; Motedayyen H; Javadi P; Jamali K; Moradi Hasan-Abad A; Atapour A; Sarab GA
Front Oncol; 2024; 14():1355064. PubMed ID: 38559560
[TBL] [Abstract][Full Text] [Related]
2. Roles of lncRNAs in pancreatic ductal adenocarcinoma: Diagnosis, treatment, and the development of drug resistance.
Jiang XY; Zhu QC; Zhang XJ; Duan T; Feng J; Sui XB; Sun XN; Mou YP
Hepatobiliary Pancreat Dis Int; 2023 Apr; 22(2):128-139. PubMed ID: 36543619
[TBL] [Abstract][Full Text] [Related]
3. Non-coding RNA biomarkers in pancreatic ductal adenocarcinoma.
Sharma GG; Okada Y; Von Hoff D; Goel A
Semin Cancer Biol; 2021 Oct; 75():153-168. PubMed ID: 33049362
[TBL] [Abstract][Full Text] [Related]
4. Long noncoding RNAs: role and contribution in pancreatic cancer.
Ramya Devi KT; Karthik D; Mahendran T; Jaganathan MK; Hemdev SP
Transcription; 2021 Feb; 12(1):12-27. PubMed ID: 34036896
[TBL] [Abstract][Full Text] [Related]
5. Multi-level integrative analysis of the roles of lncRNAs and differential mRNAs in the progression of chronic pancreatitis to pancreatic ductal adenocarcinoma.
Zhao Z; Luo Q; Liu Y; Jiang K; Zhou L; Dai R; Wang H
BMC Genomics; 2023 Mar; 24(1):101. PubMed ID: 36879212
[TBL] [Abstract][Full Text] [Related]
6. The implication of long non-coding RNAs in the diagnosis, pathogenesis and drug resistance of pancreatic ductal adenocarcinoma and their possible therapeutic potential.
Pandya G; Kirtonia A; Sethi G; Pandey AK; Garg M
Biochim Biophys Acta Rev Cancer; 2020 Dec; 1874(2):188423. PubMed ID: 32871244
[TBL] [Abstract][Full Text] [Related]
7. Emerging Role of Exosomal-Derived Long Noncoding RNAs in Human PDAC.
Long D; Tian XD; Yang YM
Visc Med; 2022 Feb; 38(1):30-36. PubMed ID: 35295891
[TBL] [Abstract][Full Text] [Related]
8. Identification of candidate miRNA biomarkers for pancreatic ductal adenocarcinoma by weighted gene co-expression network analysis.
Giulietti M; Occhipinti G; Principato G; Piva F
Cell Oncol (Dordr); 2017 Apr; 40(2):181-192. PubMed ID: 28205147
[TBL] [Abstract][Full Text] [Related]
9. Orchestrating a biomarker panel with lncRNAs and mRNAs for predicting survival in pancreatic ductal adenocarcinoma.
Wu Y; Wei J; Ming Y; Chen Z; Yu J; Mao R; Chen H; Zhou G; Fan Y
J Cell Biochem; 2018 Sep; 119(9):7696-7706. PubMed ID: 29923223
[TBL] [Abstract][Full Text] [Related]
10. LncRNA PWAR6 regulates proliferation and migration by epigenetically silencing YAP1 in tumorigenesis of pancreatic ductal adenocarcinoma.
Huang S; Li Y; Hu J; Li L; Liu Z; Guo H; Jiang B; Chen J; Li J; Xiang X; Deng J; Xiong J
J Cell Mol Med; 2021 May; 25(9):4275-4286. PubMed ID: 33834618
[TBL] [Abstract][Full Text] [Related]
11. Non-coding RNAs in Pancreatic Ductal Adenocarcinoma.
Gong R; Jiang Y
Front Oncol; 2020; 10():309. PubMed ID: 32257946
[TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNAs expressed in pancreatic ductal adenocarcinoma and lncRNA BC008363 an independent prognostic factor in PDAC.
Li J; Liu D; Hua R; Zhang J; Liu W; Huo Y; Cheng Y; Hong J; Sun Y
Pancreatology; 2014; 14(5):385-90. PubMed ID: 25200694
[TBL] [Abstract][Full Text] [Related]
13. Role of non-coding RNA in pancreatic cancer.
Lv Y; Huang S
Oncol Lett; 2019 Oct; 18(4):3963-3973. PubMed ID: 31579086
[TBL] [Abstract][Full Text] [Related]
14. Five key lncRNAs considered as prognostic targets for predicting pancreatic ductal adenocarcinoma.
Song J; Xu Q; Zhang H; Yin X; Zhu C; Zhao K; Zhu J
J Cell Biochem; 2018 Jun; 119(6):4559-4569. PubMed ID: 29239017
[TBL] [Abstract][Full Text] [Related]
15. miR-186 and 326 predict the prognosis of pancreatic ductal adenocarcinoma and affect the proliferation and migration of cancer cells.
Zhang ZL; Bai ZH; Wang XB; Bai L; Miao F; Pei HH
PLoS One; 2015; 10(3):e0118814. PubMed ID: 25742499
[TBL] [Abstract][Full Text] [Related]
16. Construction and analysis of dysregulated lncRNA-associated ceRNA network identified novel lncRNA biomarkers for early diagnosis of human pancreatic cancer.
Zhou M; Diao Z; Yue X; Chen Y; Zhao H; Cheng L; Sun J
Oncotarget; 2016 Aug; 7(35):56383-56394. PubMed ID: 27487139
[TBL] [Abstract][Full Text] [Related]
17. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
18. A novel genomic instability-derived lncRNA signature to predict prognosis and immune characteristics of pancreatic ductal adenocarcinoma.
Yang H; Zhang W; Ding J; Hu J; Sun Y; Peng W; Chu Y; Xie L; Mei Z; Shao Z; Xiao Y
Front Immunol; 2022; 13():970588. PubMed ID: 36148233
[TBL] [Abstract][Full Text] [Related]
19. Analysis of long non-coding RNA expression profiles in pancreatic ductal adenocarcinoma.
Fu XL; Liu DJ; Yan TT; Yang JY; Yang MW; Li J; Huo YM; Liu W; Zhang JF; Hong J; Hua R; Chen HY; Sun YW
Sci Rep; 2016 Sep; 6():33535. PubMed ID: 27628540
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-448 suppresses metastasis of pancreatic ductal adenocarcinoma through targeting JAK1/STAT3 pathway.
Yu DL; Zhang T; Wu K; Li Y; Wang J; Chen J; Li XQ; Peng XG; Wang JN; Tan LG
Oncol Rep; 2017 Aug; 38(2):1075-1082. PubMed ID: 28677798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
